Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 9/20 | 0.52 |
| ▸ | CA2 | P00918 | 9/20 | 0.52 |
| ▸ | CA9 | Q16790 | 9/20 | 0.52 |
| ▸ | CA12 | O43570 | 8/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14401482 | 1.00 | LMNA (0.56) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL14302583 | 1.00 | LMNA (0.56) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL4110436 | 1.00 | LMNA (0.56) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL7899944 | 1.00 | LMNA (0.56) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL16340705 | 1.00 | LMNA (0.56) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL15165006 | 1.00 | LMNA (0.56) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL15910017 | 1.00 | LMNA (0.56) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL13903997 | 1.00 | LMNA (0.56) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL8747631 | 1.00 | LMNA (0.56) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL7899946 | 1.00 | LMNA (0.56) | LMNAKMT2APOLBALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6462183-B1 | SOLID PHASE OLIGOSACCHARIDE SYNTHESIS | ALCHEMIA PTY LTD (AU) | 2002-10-08 | — | — | US | claimed |
| US-20240016828-A1 | INHIBITION OF NGLY1 FOR THE TREATMENT OF CANCER | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240016828-A1 | INHIBITION OF NGLY1 FOR THE TREATMENT OF CANCER | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240016828-A1 | INHIBITION OF NGLY1 FOR THE TREATMENT OF CANCER | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2024-01-18 | — | — | US | disclosed |
| US-11779592-B2 | Inhibition of NGLY1 for the treatment of cancer | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779592-B2 | Inhibition of NGLY1 for the treatment of cancer | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779592-B2 | Inhibition of NGLY1 for the treatment of cancer | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230272002-A1 | PHOTOREDOX PROTEIN MODIFICATION | THE ROSALIND FRANKLIN INSTITUTE (GB) | 2023-08-31 | — | — | US | disclosed |
| EP-4182327-A1 | PHOTOREDOX PROTEIN MODIFICATION | The Rosalind Franklin Institute (GB) | 2023-05-24 | — | — | EP | disclosed |
| WO-2023011597-A1 | LIGAND CONJUGATES FOR DELIVERY OF THERAPEUTICALLY ACTIVE AGENTS | Hepagene Therapeutics (HK) Limited (CN) | 2023-02-09 | — | — | WO | disclosed |
| US-5556941-A | ANTICOAGULANTS, THROMBIN INHIBITORS | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1996-09-17 | — | — | US | disclosed |
| US-5543514-A | Water-soluble sapphyrins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-08-06 | — | — | US | disclosed |
| US-5530123-A | ANTIVIRAL AND CHEMOTHERAPEUTICAL AGENT FOR CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-06-25 | — | — | US | disclosed |
| US-5457195-A | Sapphyrin derivatives and conjugates | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1995-10-10 | — | — | US | disclosed |
| EP-0413675-B1 | Method for producing synthetic N-linked glycoconjugates | MONSANTO CO (US) | 1995-05-03 | — | — | EP | disclosed |
| WO-1994009003-A1 | SAPPHYRIN DERIVATIVES, CONJUGATES AND POLYMERS THEREOF AND EXPANDED PORPHYRIN CHROMATOGRAPHIC SUPPORTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-04-28 | — | — | WO | disclosed |
| EP-0558961-A2 | Glycopeptide derivatives, process for their manufacture and pharmaceutical compositions comprising them | BEHRINGWERKE Aktiengesellschaft (DE) | 1993-09-08 | — | — | EP | disclosed |
| US-5091523-A | Bactericides, antitumor agent | GEORGETOWN UNIVERSITY (US) | 1992-02-25 | — | — | US | disclosed |
| US-4280953-A | Glycosylated analogs of somatostatin | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1981-07-28 | — | — | US | disclosed |
| US-4157439-A | ANTITUMOR, LOW TOXICITY, NONHYDROLYZING | SUAMI T (JP) | 1979-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272002-A1 | PHOTOREDOX PROTEIN MODIFICATION | PPOX, CACYBP, BRI3BP | LMNA 4279/4885KMT2A 3404/4885POLB 3843/4885 |
| US-11779592-B2 | Inhibition of NGLY1 for the treatment of cancer | NGLY1, GALNT1, GALNT10 | LMNA 2369/4885KMT2A 4129/4885POLB 3957/4885 |
| US-20240016828-A1 | INHIBITION OF NGLY1 FOR THE TREATMENT OF CANCER | NGLY1, GALNT1, GALNT10 | LMNA 2401/4885KMT2A 3992/4885POLB 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.